Scinai Immunotherapeutics Successfully Meets Nasdaq Minimum Bid Price Requirements After Regulatory Review

Scinai Immunotherapeutics Regains Nasdaq Compliance

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a pioneering biopharmaceutical firm focused on advanced immunology treatments, recently achieved a significant milestone by regaining compliance with Nasdaq’s minimum bid price requirement. After a thorough review, Nasdaq confirmed that Scinai met the necessary criteria under Listing Rule 5550(a)(2), closing the matter that had previously raised concerns about the company's share price.

On March 12, 2026, Scinai was informed by Nasdaq that its American Depositary Shares (ADS) failed to maintain a minimum bid price of $1.00 over the preceding 30 consecutive business days. The company's management understood the gravity of the situation and took immediate corrective actions to stabilize and enhance its stock performance.

In a notable turn of events, from August 21, 2026 to September 17, 2026, Scinai’s ADS closing bid price successfully remained at or above $1.00, thereby allowing the company to re-establish compliance. This confirmation from Nasdaq is pivotal for Scinai, particularly as it creates an opportunity for enhanced visibility and credibility in the market.

Amir Reichman, Scinai’s CEO, expressed relief and gratitude following the positive news: "Receiving Nasdaq's confirmation closes an important compliance matter for Scinai. We appreciate Nasdaq Staff's review and constructive engagement throughout the process. With this matter resolved, our focus remains on the commercial execution at Scinai Biopharma Services and the disciplined advancement of our NanoAb programs."

Company Overview and Future Focus

Scinai Immunotherapeutics specializes in innovative solutions in the field of immunology. The company is at the forefront of developing cutting-edge therapies through its NanoAb platform, partnering with prestigious institutions such as the Max Planck Society and the University Medical Center Göttingen. Additionally, Scinai operates Scinai Biopharma Services, a Contract Development and Manufacturing Organization (CDMO) that provides essential services to biotechnology and pharmaceutical companies, leveraging state-of-the-art facilities in Jerusalem and Yavne, Israel.

Notably, regaining compliance is a critical component of Scinai's larger strategy. It enables the company to focus on its core business objectives, which include expanding its CDMO operations and improving revenue streams. The company's leadership is committed to navigating the biopharmaceutical landscape with a strong emphasis on innovative research, development, and customer collaboration.

Despite the challenges faced, including the pressure of maintaining stock prices amidst external market conditions, Scinai's management has articulated confidence in their strategic roadmap. Their commitment to advancing their innovative therapies and strengthening their production capabilities positions Scinai favorably for future growth.

For potential investors and stakeholders, the news of regained Nasdaq compliance serves as a signal of resilience within Scinai's operations. The company is intent on converting this success into tangible business progress while continuing to abide by the stringent regulations set forth by the Nasdaq.

As they look ahead, Scinai Immunotherapeutics is poised to leverage its restored status to further engage with the market, drive innovation in immunology treatments, and solidify its standing as a leader in the biopharmaceutical industry. For more details on Scinai's initiatives, please visit their official website at www.scinai.com.